Karen Dawaf’s Post

Arrowpoint Advisory’s Healthcare and Debt Advisory teams have advised LDC on its investment in Panthera Biopartners, the UK’s largest Site Management Organisation for commercial clinical trials. The investment, alongside reinvestment from existing shareholders BGF, will support Panthera’s expansion plans and further enhance its clinical capabilities. With LDC’s support, Panthera will seek to further expand its operations in the UK and Europe, increase its number of clinical sites, invest in technology, and scale its trial delivery capabilities. Karen Dawaf, Managing Director at Arrowpoint Advisory who led on the deal, commented: “It was a pleasure to support Grant, Alex, and the LDC Manchester team on this pivotal transaction in the SMO space. We’re proud to have played a role in this milestone and look forward to seeing the exciting opportunities that lie ahead for Stuart, Chris, Rory and the wider Panthera team.” Neil Smith, Managing Director of Debt Advisory at Arrowpoint Advisory, added: “It was great to work with LDC and Panthera on this important transaction. Panthera’s excellent track record and outstanding market reputation ensured that we were able to provide a highly flexible and best-in-market financing package, which has been tailored to facilitate the exciting growth prospects of the company. We wish LDC and Panthera all the best with their expansion plans.” For more information about how we supported LDC on its investment in Panthera, read more here: https://lnkd.in/eTKrBNRP #Healthcare #PrivateEquity #NorthWest #AcquisitionFinancing